dm+d

Unassigned

New Medicines

Osteoarthritis

Information

New molecular entity
Teva
Regeneron

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Nerve growth factor inhibitor
Osteoarthritis (OA) is age-related, with risk increasing from late-40s; of all people aged 45 and over, estimates suggest that around 18% will have sought treatment for OA of the knee and 11% for OA of the hip: about a third of cases may be classed as severe and thus requiring special attention [3]
Osteoarthritis
Subcutaneous injection